Variables | Time point | MSA | MSA-P | MSA-C | p-value | Male MSA | Female MSA | p-value |
---|---|---|---|---|---|---|---|---|
Number | 220 | 107 | 113 | - | 114 | 106 | - | |
Age (years) | Baseline | 59.32 ± 8.09 | 60.73 ± 8.20 | 57.97 ± 7.78 | 0.022* | 58.96 ± 8.75 | 59.71 ± 7.33 | 0.312 |
Sex (male, %) | Baseline | 114, 51.8% | 55, 51.4% | 59, 52.2% | 0.904 | 114, 100% | 0, 0% | - |
Diagnosis subtype (MSA-P, %) | Baseline | 107, 48.6% | 107, 100% | 0, 0% | - | 55, 48.2% | 52, 49.1% | 0.904 |
Age of onset (years) | Baseline | 57.64 ± 8.09 | 59.06 ± 8.23 | 56.29 ± 7.74 | 0.021* | 57.40 ± 8.73 | 57.90 ± 7.36 | 0.466 |
Disease duration (years) | Baseline | 1.68 ± 0.75 | 1.67 ± 0.78 | 1.68 ± 0.73 | 0.814 | 1.55 ± 0.74 | 1.81 ± 0.75 | 0.016* |
UMSARS-I score | Baseline | 12.71 ± 5.79 | 12.94 ± 5.29 | 12.50 ± 6.25 | 0.423 | 12.27 ± 5.65 | 13.19 ± 5.93 | 0.154 |
1-year FU | 18.05 ± 7.10 | 17.21 ± 7.25 | 18.86 ± 6.90 | 0.086 | 17.63 ± 7.22 | 18.51 ± 6.98 | 0.402 | |
2-year FU | 23.60 ± 7.47(n=90) | 23.39 ± 8.53(n=46) | 23.82 ± 6.27(n=44) | 0.531 | 23.82 ± 8.40(n=44) | 23.39 ± 6.55(n=46) | 0.994 | |
UMSARS-II score | Baseline | 15.20 ± 5.87 | 15.64 ± 5.67 | 14.79 ± 6.04 | 0.199 | 14.57 ± 5.32 | 15.89 ± 6.35 | 0.100 |
1-year FU | 21.57 ± 7.10 | 20.43 ± 7.32 | 22.65 ± 6.75 | 0.020* | 20.66 ± 6.88 | 22.56 ± 7.24 | 0.069 | |
2-year FU | 26.66 ± 7.49(n=90) | 27.33 ± 8.14(n=46) | 25.95 ± 6.78(n=44) | 0.645 | 26.93 ± 7.97(n=44) | 26.39 ± 7.08(n=46) | 0.923 | |
UMSARS-IV score | Baseline | 1.67 ± 0.74 | 1.67 ± 0.74 | 1.67 ± 0.74 | 0.974 | 1.50 ± 0.61 | 1.86 ± 0.81 | < 0.001* |
1-year FU | 2.48 ± 0.91 | 2.36 ± 0.88 | 2.59 ± 0.92 | 0.079 | 2.27 ± 0.86 | 2.70 ± 0.92 | < 0.001* | |
2-year FU | 3.02 ± 1.02(n=90) | 3.04 ± 1.10(n=46) | 3.00 ± 0.94(n=44) | 0.986 | 2.84 ± 1.03(n=44) | 3.20 ± 0.98(n=46) | 0.062 | |
UMSARS total score | Baseline | 27.92 ± 10.81 | 28.59 ± 10.03 | 27.28 ± 11.50 | 0.232 | 26.84 ± 10.05 | 29.08 ± 11.50 | 0.120 |
1-year FU | 39.63 ± 13.51 | 37.64 ± 13.87 | 41.51 ± 12.94 | 0.033* | 38.29 ± 13.41 | 41.07 ± 13.53 | 0.151 | |
2-year FU | 50.26 ± 14.39(n=90) | 50.72 ± 16.22(n=46) | 49.77 ± 12.37(n=44) | 0.961 | 50.75 ± 15.84(n=44) | 49.78 ± 13.02(n=46) | 0.865 | |
OH (%) | Baseline | 83, 37.7% | 34, 31.8% | 49, 43.4% | 0.076 | 44, 38.6% | 39, 36.8% | 0.783 |
1-year FU | 108, 49.1% | 46, 43.0% | 62, 54.9% | 0.078 | 53, 46.5% | 55, 51.9% | 0.424 | |
2-year FU | 51, 56.7%(n=90) | 28, 60.9%(n=46) | 23, 52.3%(n=44) | 0.411 | 26, 59.1%(n=44) | 25, 54.3%(n=46) | 0.650 | |
MoCA score | Baseline | 23.90 ± 3.25(n=211) | 23.99 ± 3.35(n=100) | 23.82 ± 3.17(n=111) | 0.678 | 24.30 ± 3.31(n=113) | 23.44 ± 3.14(n=98) | 0.052 |
1-year FU | 22.09 ± 3.63(n=211) | 22.43 ± 3.73(n=100) | 21.79 ± 3.52(n=111) | 0.192 | 22.41 ± 3.64(n=113) | 21.73 ± 3.60(n=98) | 0.196 | |
2-year FU | 21.09 ± 4.32(n=78) | 21.84 ± 4.11(n=37) | 20.41 ± 4.44(n=41) | 0.166 | 21.53 ± 4.28(n=38) | 20.68 ± 4.37(n=40) | 0.272 | |
PDSS-2 score | Baseline | 9.60 ± 6.08 | 11.13 ± 6.52 | 8.14 ± 5.27 | < 0.001# | 8.81 ± 5.63 | 10.44 ± 6.46 | 0.064 |
ESS score | Baseline | 4.81 ± 4.66 | 6.13 ± 5.06 | 3.57 ± 3.87 | < 0.001# | 5.10 ± 4.78 | 4.51 ± 4.53 | 0.359 |
RBDSQ score | Baseline | 5.04 ± 3.40 | 4.92 ± 3.11 | 5.15 ± 3.66 | 0.917 | 4.96 ± 3.40 | 5.11 ± 3.40 | 0.711 |
2-year change in the PDSS-2 score | - | 1.23 ± 3.26(n=90) | 1.24 ± 3.94(n=46) | 1.22 ± 2.41(n=44) | 0.977 | 0.63 ± 2.61(n=44) | 1.80 ± 3.73(n=46) | 0.051 |
2-year change in the ESS score | - | 1.63 ± 2.57(n=90) | 1.72 ± 2.78(n=46) | 1.52 ± 2.35(n=44) | 0.865 | 2.32 ± 2.75(n=44) | 0.96 ± 2.21(n=46) | 0.025* |
2-year change in the RBDSQ score | - | 0.28 ± 1.76(n=90) | 0.52 ± 1.60(n=46) | 0.02 ± 1.89(n=44) | 0.429 | 0.26 ± 1.83(n=44) | 0.30 ± 1.70(n=46) | 0.958 |
Presence of PD-SP (n, %) | Baseline | 32, 14.5% | 22, 20.6% | 10, 8.8% | 0.016# | 13, 11.4% | 19, 17.9% | 0.170 |
Presence of EDS (n, %) | Baseline | 39, 17.7% | 27, 25.2% | 12, 10.6% | 0.006# | 24, 21.1% | 15, 14.2% | 0.180 |
Presence of RBD (n, %) | Baseline | 114, 51.8% | 55, 51.4% | 59, 52.2% | 0.904 | 57, 50.0% | 57, 53.8% | 0.576 |
LEDD (mg/d) | Baseline | 168.33 ± 236.76 | 252.53 ± 271.58 | 88.61 ± 163.15 | < 0.001* | 188.69 ± 238.31 | 146.44 ± 234.23 | 0.073 |
Use of sleep-related medications (n, %) | Baseline | 16, 7.3% | 9, 8.4% | 7, 6.2% | 0.527 | 9, 7.9% | 7, 6.6% | 0.713 |